BioDelivery Sciences International

News & Media

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released via email or RSS.

Archives: Search / 2012 / 2011

Feb 22, 2012
US Patent Office Rejects All Claims in Second MonoSol Patent
Feb 16, 2012
BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
Patent extends exclusivity protection for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone through 2027
Jan 6, 2012
BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
BDSI to receive up to $180 million plus royalties
Dec 29, 2011
ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products
FDA's approval of class-wide REMS puts ONSOLIS in an improved competitive position
Dec 20, 2011
BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study
 
 
Media inquiries

Contact Al Medwar

at 919-582-9050

amedwar@bdsi.com